Satoh Hiroaki, Kurishima Koichi, Nakamura Ryota, Ishikawa Hiroichi, Kagohashi Katsunori, Ohara Gen, Ishikawa Shigemi, Ohtsuka Morio, Sekizawa Kiyohisa, Hizawa Nobuyuki
Division of Respiratory Medicine, Institute of Clinical Medicine, University of Tsukuba, Tsukuba-city, Ibaraki 305-8575, Japan.
Lung Cancer. 2009 Jul;65(1):112-8. doi: 10.1016/j.lungcan.2008.10.020. Epub 2008 Dec 2.
The purpose of this study is to examine clinical and pathological features, treatment modality approaches in the elderly, especially in patients aged 80 years and older.
From the databases at two educational hospitals during the period from January 1978 and December 2007, medical records of lung cancer patients were retrospectively reviewed. The patient population was divided into three age groups: less than 70 years (the <70 age group), 70-79 years (the 70-79 age group), and 80 years or older (the > or =80 age group). Time trends were also studied in two-time intervals: first study period up to 1997, which represents past practice standards, the second study period up to 2007, which represents contemporary practice.
Patients aged 80 years and older comprised 7.5% of 2775 consecutive patients with lung cancer, and there was a rapid increase in the proportion of patients aged 80 years or older from the earlier to the later time period. The > or =80 age group had higher proportion of poor performance status (PS) and comorbid disease than the <70 age group and the 70-79 age group. Unchanged proportion of patients with poor PS and advanced disease at presentation were observed in the > or =80 age group. The > or =80 age group was less likely to be subjected to surgery or chemotherapy, and had inferior outcomes when compared with the 70-79 age group and the <70 age group. Survival improvement was not observed in the > or =80 age group. Multivariate analysis showed good PS, early clinical stage and surgery were favorable prognostic factors in the > or =80 age group.
In order to improve the outcome, detection of early stage lung cancer in patients with good PS and thorough pretreatment evaluation for appropriate treatment are indeed essential even for the > or =80 age group of patients.
本研究旨在探讨老年患者,尤其是80岁及以上患者的临床和病理特征以及治疗方式。
回顾性分析1978年1月至2007年12月期间两家教学医院数据库中肺癌患者的病历。将患者人群分为三个年龄组:小于70岁(<70岁年龄组)、70 - 79岁(70 - 79岁年龄组)和80岁及以上(≥80岁年龄组)。还在两个时间段研究了时间趋势:第一个研究期截至1997年,代表过去的实践标准;第二个研究期截至2007年,代表当代实践。
80岁及以上患者占2775例连续肺癌患者的7.5%,且从早期到后期,80岁及以上患者的比例迅速增加。≥80岁年龄组的功能状态(PS)差和合并症的比例高于<70岁年龄组和70 - 79岁年龄组。在≥80岁年龄组中,初诊时PS差和疾病晚期的患者比例未发生变化。≥80岁年龄组接受手术或化疗的可能性较小,与70 - 79岁年龄组和<70岁年龄组相比,预后较差。在≥80岁年龄组中未观察到生存改善。多因素分析显示,PS良好、临床分期早和手术是≥80岁年龄组的有利预后因素。
为了改善预后,即使对于≥80岁年龄组的患者,检测PS良好的早期肺癌并进行全面的预处理评估以进行适当治疗确实至关重要。